stockrowValneva SE Sponsored ADR
VALN Healthcare Biotechnology
Valneva SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $197.6 million, up 7.69% from fiscal 2024.
- Revenue
- −17.3%
- EPS
- −222.1%
- Free cash flow
- −56.1%
- Total debt
- +12.1%
Quarter to June 2026, against a year earlier
Follow VALN
Alert me
Valneva SE Sponsored ADR (VALN) EV/Sales
As of 6 November 2026, Valneva SE Sponsored ADR (VALN) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.3× (April 2023) to 20.8× (November 2021); the current reading is higher than 49% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.1× | 97.77% |
| FY2024 | 2.1× | (26.63%) |
| FY2023 | 2.8× | 31.60% |
| FY2022 | 2.2× | (87.22%) |
| FY2021 | 16.9× | 100.05% |
| FY2020 | 8.4× | 0.00% |
| FY2019 | 8.4× | 0.00% |
| FY2018 | 8.4× | 0.00% |
| FY2017 | 8.4× | 0.00% |
| FY2016 | 8.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 3.9× | 23.98% |
| Mar 2025 | 3.2× | (8.91%) |
| Mar 2024 | 3.5× | 10.56% |
| Sep 2023 | 3.2× | 14.83% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NGNE Neurogene Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| VALN Valneva SE Sponsored ADR | 3.5× |
| ACRS Aclaris Therapeutics, Inc. compare | 74.4× |
| ENTX Entera Bio Ltd. compare | 643× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | 759× |
| IAM Iambic Therapeutics, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)